2025. 10. 15
New C2H Report: Zolbetuximab (Vyloy)
2025. 09. 10
New C2H Report: Luspatercept (Reblozyl)
2025. 07. 09
New C2H Report: lecanemab (Leqembi)
View all news
2019. 03. 06
International symposium - Current status and future role of HTA in Japan and other countries
View all events